Simvastatin stimulates apoptosis in cholangiocarcinoma by inhibition of Rac1 activity

Digestive and Liver Disease

Volumn 43, Issue 5, 2011, Pages 395-403

  Miller, Timothy ^a   Yang, Fuquan ^b   Wise, Candace E ^a   Meng, Fanyin ^a   Priester, Sally ^a   Munshi, Md Kamruzzaman ^a   Guerrier, Micheleine ^a   Dostal, David E ^a   Glaser, Shannon S ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cholangiocarcinoma; Rac1; Simvastatin

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVALONIC ACID; RAC1 PROTEIN; SIMVASTATIN;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN HIBEPIC; CELL STRAIN HUCCT1; CELL STRAIN HUH 28; CELL STRAIN MZ CHA 1; CELL STRAIN SG231; CELL STRAIN TFK 1; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; LIPID RAFT; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CELL SURVIVAL; CHOLANGIOCARCINOMA; EPITHELIAL CELLS; HUMANS; RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; SIMVASTATIN; STATISTICS, NONPARAMETRIC;

EID: 79953270760     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2011.01.010     Document Type: Article

References (70)

1. Alpini G., Prall R.T., LaRusso N.F. The pathobiology of biliary epithelia. The Liver; Biology & Pathobiology 2001, 421-435. Lippincott Williams & Wilkins, Philadelphia, PA. 4th ed. I.M. Arias, J.L. Boyer, F.V. Chisari, N. Fausto, W. Jakoby, D. Schachter, D.A. Shafritz (Eds.).
2. Blendis L., Halpern Z. An increasing incidence of cholangiocarcinoma: why?. Gastroenterology 2004, 127:1008-1009.
3. Lee S., Oh S.Y., Kim B.G., et al. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (Conti-Fam) in gemcitabine-pretreated pancreatic and biliary tract cancer. Am J Clin Oncol 2009.
4. Blechacz B., Gores G.J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008, 48:308-321.
5. Istvan E.S., Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001, 292:1160-1164.
6. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992, 33:1569-1582.
7. Sassano A., Platanias L.C. Statins in tumor suppression. Cancer Lett 2008, 260:11-19.
8. Karp I., Behlouli H., Lelorier J., et al. Statins and cancer risk. Am J Med 2008, 121:302-309.
9. Brown A.J. Cholesterol, statins and cancer. Clin Exp Pharmacol Physiol 2007, 34:135-141.
10. Zhou Q., Liao J.K. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J 2010, 74:818-826.
11. Blum A., Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009, 203:325-330.
12. Elewa H.F., El-Remessy A.B., Somanath P.R., et al. Diverse effects of statins on angiogenesis: new therapeutic avenues. Pharmacotherapy 2010, 30:169-176.
13. Sassano A., Katsoulidis E., Antico G., et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 2007, 67:4524-4532.
14. Cho S.J., Kim J.S., Kim J.M., et al. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 2008, 123:951-957.
15. Ghosh-Choudhury N., Mandal C.C., Ghosh Choudhury G. Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal 2010, 22:749-758.
16. Sekine Y., Furuya Y., Nishii M., et al. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochem Biophys Res Commun 2008, 372:356-361.
17. Saito A., Saito N., Mol W., et al. Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res 2008, 18:85-94.
18. Ghavami S., Mutawe M.M., Hauff K., et al. Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c. Biochim Biophys Acta 2010, 1803:452-467.
19. Gbelcova H., Lenicek M., Zelenka J., et al. Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer 2008, 122:1214-1221.
20. Reedquist K.A., Pope T.K., Roess D.A. Lovastatin inhibits proliferation and differentiation and causes apoptosis in lipopolysaccharide-stimulated murine B cells. Biochem Biophys Res Commun 1995, 211:665-670.
21. Perez-Sala D., Collado-Escobar D., Mollinedo F. Intracellular alkalinization suppresses lovastatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent endonuclease. J Biol Chem 1995, 270:6235-6242.
22. Elson C.E., Peffley D.M., Hentosh P., et al. Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc Soc Exp Biol Med 1999, 221:294-311.
23. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719.
24. Brown J.H., Del Re D.P., Sussman M.A. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 2006, 98:730-742.
25. Brown M.S., Goldstein J.L. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980, 21:505-517.
26. Fritz G., Kaina B. Rho GTPases: promising cellular targets for novel anticancer drugs. Curr Cancer Drug Targets 2006, 6:1-14.
27. Jaffe A.B., Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005, 21:247-269.
28. Bosco E.E., Mulloy J.C., Zheng Y. Rac1 GTPase: a " Rac" of all trades. Cell Mol Life Sci 2009, 66:370-374.
29. del Pozo M.A., Alderson N.B., Kiosses W.B., et al. Integrins regulate Rac targeting by internalization of membrane domains. Science 2004, 303:839-842.
30. Michaely P.A., Mineo C., Ying Y.S., et al. Polarized distribution of endogenous Rac1 and RhoA at the cell surface. J Biol Chem 1999, 274:21430-21436.
31. del Pozo M.A., Balasubramanian N., Alderson N.B., et al. Phospho-caveolin-1 mediates integrin-regulated membrane domain internalization. Nat Cell Biol 2005, 7:901-908.
32. del Pozo M.A., Price L.S., Alderson N.B., et al. Adhesion to the extracellular matrix regulates the coupling of the small GTPase Rac to its effector PAK. EMBO J 2000, 19:2008-2014.
33. Dovas A., Couchman J.R. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J 2005, 390:1-9.
34. Yoshida T., Zhang Y., Rivera Rosado L.A., et al. Blockade of Rac1 activity induces G(1) cell cycle arrest or apoptosis in breast cancer cells through downregulation of cyclin D1, survivin, and X-linked inhibitor of apoptosis protein. Mol Cancer Ther 2010, 9:1657-1668.
35. Shinozaki S., Inoue Y., Yang W., et al. Farnesyltransferase inhibitor improved survival following endotoxin challenge in mice. Biochem Biophys Res Commun 2010, 391:1459-1464.
36. Vogt A., Sun J., Qian Y., et al. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem 1997, 272:27224-27229.
37. Narumiya S., Ishizaki T., Uehata M. Use and properties of ROCK-specific inhibitor Y-27632. Methods Enzymol 2000, 325:273-284.
38. Desire L., Bourdin J., Loiseau N., et al. RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases Abeta production in vitro and in vivo. J Biol Chem 2005, 280:37516-37525.
39. Knuth A., Gabbert H., Dippold W., et al. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol 1985, 1:579-596.
40. Kusaka Y., Muraoka A., Tokiwa T., et al. Establishment and characterization of a human cholangiocellular carcinoma cell line. Hum Cell 1988, 1:92-94.
41. Saijyo S., Kudo T., Suzuki M., et al. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med 1995, 177:61-71.
42. Kanno N., Glaser S., Chowdhury U., et al. Gastrin inhibits cholangiocarcinoma growth through increased apoptosis by activation of Ca2+-dependent protein kinase C-alpha. J Hepatol 2001, 34:284-291.
43. Han C., Leng J., Demetris A.J., et al. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res 2004, 64:1369-1376.
44. Wu T., Han C., Lunz J.G., et al. Involvement of 85-kd cytosolic phospholipase A(2) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells. Hepatology 2002, 36:363-373.
45. Han C., Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 2005, 280:24053-24063.
46. Onori P., Wise C., Gaudio E., et al. Secretin inhibits cholangiocarcinoma growth via dysregulation of the cAMP-dependent signaling mechanisms of secretin receptor. Int J Cancer 2009.
47. Francis H., Glaser S., Ueno Y., et al. cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway. J Hepatol 2004, 41:528-537.
48. DeMorrow S., Glaser S., Francis H., et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem 2007, 282:13098-13113.
49. Ogunwobi O.O., Beales I.L. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008, 103:825-837.
50. Ahn K.S., Sethi G., Aggarwal B.B. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway. Biochem Pharmacol 2008, 75:907-913.
51. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
52. Brunner T.B., Hahn S.M., Gupta A.K., et al. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 2003, 63:5656-5668.
53. LeSage E.G., Alvaro D., Benedetti A., et al. Cholinergic system modulates growth, apoptosis, and secretion of cholangiocytes from bile duct-ligated rats. Gastroenterology 1999, 117:191-199.
54. Nonaka M., Uota S., Saitoh Y., et al. Role for protein geranylgeranylation in adult T-cell leukemia cell survival. Exp Cell Res 2009, 315:141-150.
55. Li Y.C., Park M.J., Ye S.K., et al. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol 2006, 168:1107-1118. [quiz 404-5].
56. Feingold K.R., Wiley M.H., Moser A.H., et al. Altered activation state of hydroxymethylglutaryl-coenzyme A reductase in liver tumors. Arch Biochem Biophys 1983, 226:231-241.
57. Gregg R.G., Sabine J.R., Wilce P.A. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in rat liver and Morris hepatomas 5123C, 9618A and 5123t.c. Biochem J 1982, 204:457-462.
58. Bennis F., Favre G., Le Gaillard F., et al. Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. Int J Cancer 1993, 55:640-645.
59. Kawata S., Takaishi K., Nagase T., et al. Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res 1990, 50:3270-3273.
60. Caruso M.G., Notarnicola M., Santillo M., et al. Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor. Anticancer Res 1999, 19:451-454.
61. Johnson J.M., Castle J., Garrett-Engele P., et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003, 302:2141-2144.
62. Hirsch H.A., Iliopoulos D., Joshi A., et al. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 2010, 17:348-361.
63. Zhuang L., Kim J., Adam R.M., et al. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005, 115:959-968.
64. Dimitroulakos J., Ye L.Y., Benzaquen M., et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 2001, 7:158-167.
65. Kusama T., Mukai M., Iwasaki T., et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 2001, 61:4885-4891.
66. Dimitroulakos J., Nohynek D., Backway K.L., et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 1999, 93:1308-1318.
67. Newman A., Clutterbuck R.D., Powles R.L., et al. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma 1997, 24:533-537.
68. Rzepczynska I.J., Piotrowski P.C., Wong D.H., et al. Role of isoprenylation in simvastatin-induced inhibition of ovarian theca-interstitial growth in the rat. Biol Reprod 2009, 81:850-855.
69. Ifere G.O., Barr E., Equan A., et al. Differential effects of cholesterol and phytosterols on cell proliferation, apoptosis and expression of a prostate specific gene in prostate cancer cell lines. Cancer Detect Prev 2009, 32:319-328.
70. Clendening J.W., Pandyra A., Boutros P.C., et al. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci USA 2010, 107:15051-15056.